BALTIMORE--(BUSINESS WIRE)--NeuroIntact Inc., a company pioneering a new modality in targeted temperature management (TTM) to address stroke and traumatic brain injury, has appointed Robert Kline to its Board of Directors. Kline’s 25 years of success growing innovative companies in the temperature management space will advance the company’s pathway toward commercialization of its intranasal delivery method for TTM.
Mr. Kline is considered one of the pioneers of TTM, as the founder of Medivance, which is focused on therapeutic temperature management products to improve clinical outcomes in critical conditions such as cardiac arrest, traumatic brain injury, and stroke. Medivance was acquired by C. R. Bard (now Becton Dickinson) for approximately $250 million in 2011. Mr. Kline also co-founded ViroCyt, which was acquired by Sartorius AG in 2016 for ten times its revenue, and served as CEO of Bolder Surgical, which was acquired by Hologic, Inc. for $160 million in 2021.
“NeuroIntact’s non-invasive intranasal delivery technology to cool the brain represents a sea change in TTM, and I am extremely enthusiastic about its potential,” said Kline. “NeuroIntact’s cooling approach can be administered without the use of sedation drugs, and with the benefit of nonexistent patient shivering. As a result, I believe this will provide the proven benefit of cooling therapy to a much larger group of patients than treated today.”
Bill Niland, NeuroIntact’s Board Chair and a serial life sciences entrepreneur including the founding of Vapotherm and Harpoon Medical, commented, “Bob’s extensive experience in growing innovative medical companies will be instrumental as we advance our mission to deliver revolutionary solutions for TTM technology.”
Founder and President of NeuroIntact Inc., Bryan Nicholson, added, “We have intentionally cultivated a board of directors composed of proven experts in airway management and TTM. I feel so fortunate to have this amazing trust behind me to accomplish our mission of advancing the science of TTM and provide valuable solutions to healthcare providers and patients everywhere.”
Niland and Kline are joined on the Board by Kevin Thibodeau, who has 25 years of experience, most recently in market adoption and strategic commercialization at Vapotherm.
ABOUT NEUROINTACT
Founded in 2023, NeuroIntact is a med-tech start-up company specializing in non-invasive targeted temperature management solutions. Its patented VCool™ TTM system targets the brain and body using nasal cannulation to reduce intracranial pressure and control patient core temperature without systemic side effects. This portable, technology enhances patient care with a drug-free approach, without shivering.
NeuroIntact will be presenting the first in human trial results on 11.12.24 at Medica in Dusseldorf, Germany.
VCOOL™ IS AN INVESTIGATIONAL DEVICE AND IS NOT CLEARED FOR USE IN THE UNITED STATES.
